AIM ImmunoTech expands Ampligen long COVID patent coverage through 2041
AIM ImmunoTech expands its Ampligen® global patent estate for long COVID protection in Europe and the United Kingdom through 2041.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.